Lilly launches UK version of LillyDirect delivery service, starting with Mounjaro
A home-delivery channel for Mounjaro has opened in Britain, where private prescriptions drive much of the market; it works differently from LillyDirect in the US, where patients can buy directly.
Eli Lilly launched LillyDirect in the United Kingdom on June 25, 2026, extending the direct-to-consumer channel it already runs in the United States into a market where its weight-loss and diabetes drug Mounjaro (tirzepatide) is largely reached through private prescriptions [1]. The first medicine offered through the UK service is injectable Mounjaro, which is approved there for weight loss and for type 2 diabetes [1].
The UK version works differently from the American one. In the US, LillyDirect operates as a direct-to-patient sales channel [1]. UK law prohibits drug manufacturers from shipping prescription-only medicines directly to patients, so the British service is a post-prescription dispensing and delivery operation that runs through a network of private, UK-regulated healthcare organizations [1]. Once an eligible private healthcare company registers, it can issue private electronic prescriptions. Lilly's dispensing partners — currently Blueco Healthcare's Onescript service and Pharmacy2U — then process and deliver the medicine in discreet packaging to the patient's home, with real-time delivery tracking, according to the drugmaker [1]. Lilly said it plays no role in clinical decisions relating to patient care [1].
Mounjaro is approved in the UK for weight loss and type 2 diabetes but can be hard to obtain through the National Health Service because of restrictions on who qualifies [1]. Many UK users therefore rely on private prescriptions, which the company says can expose them to falsified copies of the pen that may lack any active ingredient or, as reported in some cases internationally, contain potentially hazardous drugs such as insulin [1]. Lilly said the new service ensures that only "authentic, Lilly-manufactured medicines are delivered to patients, helping to safeguard against the risk of counterfeit products entering the supply chain" [1].
"This year marks 150 years since the founding of Eli Lilly and Company. For a century and a half, our founding purpose – to make life better for patients – has driven every innovation we have pursued," said Khalil Asmar, vice president of cardiometabolic health at Lilly UK & Northern Europe. "The launch of LillyDirect in the UK is a continuation of that legacy: using the tools and technologies available today to better serve patients tomorrow," he added. "We are committed to ensuring that once a patient has been prescribed a Lilly medicine, receiving it is as simple, secure, and straightforward as possible" [1].
Why it matters for patients
For people in Britain, the channel does not change who can get a prescription. A private clinician still has to write it, and the medicine is still a private purchase rather than an NHS one [1]. Pricing for the UK service has not been reported, and Lilly did not say whether the service would be cheaper than existing private pharmacies. Lilly also stated it takes no part in clinical decisions, so questions about dose, eligibility or monitoring remain with the prescribing clinician [1].
The stated benefit is supply-chain security. The UK private market for tirzepatide has been linked to falsified pens that may contain no active ingredient or hazardous drugs such as insulin [1]. Medicines bought through this route are dispensed by registered UK partners and delivered to the home [1].
Mounjaro is tirzepatide, a different molecule from semaglutide, the ingredient in Ozempic, Wegovy and Rybelsus [1]. The UK launch does not change US supply, US pricing or US insurance coverage for any GLP-1 or GIP/GLP-1 medicine, and no US changes tied to this announcement were disclosed. What the launch does show is how the direct delivery model is being adapted country by country, since the US approach of shipping directly to patients cannot be copied where local law forbids it [1].
What happens next
Lilly said it may in time extend LillyDirect in the UK to other medicines, potentially including Foundayo (orforglipron), its oral GLP-1 agonist, which is under review by the UK's Medicines and Healthcare products Regulatory Agency and could be available for private prescription before the end of the year if approved [1]. No decision date from the MHRA has been announced, and the company has not said whether it plans to bring the service to other countries.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.